Citius Pharmaceuticals, Inc. (CTXR)

Citius Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020
Net Income	-39.68	-39.14	-32.54	-33.64	-23.05	-17.55
Depreciation & Amortization	0.21	0.21	0.19	0.18	0.16	0.15
Stock-Based Compensation	11.51	12.12	6.72	4.28	1.52	1.33
Other Operating Activities	-0.1	0.29	0.58	0.58	-0.17	-
Change in Inventory	-8.25	-2.13	-	-	-	-
Change in Accounts Payable	4.72	2	1.76	-0.11	-0.58	-0.86
Change in Other Net Operating Assets	4.79	-1.55	-5.77	0.35	-2.14	-0.01
Operating Cash Flow	-26.79	-28.2	-29.06	-28.36	-24.25	-16.93
Capital Expenditures	-	-	-	-	-0.01	-0
Sale (Purchase) of Intangibles	-5	-5	-	-	-40	-
Investing Cash Flow	-5	-5	-	-	-40.01	-0
Long-Term Debt Issued	-	-	-	-	-	0.16
Total Debt Issued	-	-	-	-	-	0.16
Short-Term Debt Repaid	-	-	-	-	-0.17	-
Total Debt Repaid	-	-	-	-	-0.17	-
Net Debt Issued (Repaid)	-	-	-	-	-0.17	0.16
Issuance of Common Stock	16.38	13.8	15.03	-	127.71	24.27
Other Financing Activities	-3.83	-3.83	-1.2	-	-7.07	-1.54
Financing Cash Flow	12.55	9.97	13.83	-	120.47	22.9
Net Cash Flow	-19.25	-23.23	-15.23	-28.36	56.21	5.97
Free Cash Flow	-26.79	-28.2	-29.06	-28.36	-24.26	-16.93
Free Cash Flow Per Share	-3.82	-4.19	-4.80	-4.85	-5.58	-10.81
Cash Interest Paid	-	-	-	-	0.04	-
Levered Free Cash Flow	9.93	8.02	-19.85	-15.94	-55.61	-10.34
Unlevered Free Cash Flow	9.93	8.02	-19.85	-15.94	-55.61	-10.33
Change in Net Working Capital	-29.88	-26.93	3.81	-0.42	2.58	0.74

Updated Feb 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q